Affiliation:
1. Seasun Biomaterials, Inc., Daejeon 34015, Republic of Korea
2. Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul 05030, Republic of Korea
Abstract
Benign lung diseases are common and often do not require specific treatment, but they pose challenges in the distinguishing of them from lung cancer during low-dose computed tomography (LDCT). This study presents a comprehensive methylation analysis using real-time PCR for minimally invasive diagnoses of lung cancer via employing BALF exosome DNA. A panel of seven epigenetic biomarkers was identified, exhibiting specific methylation patterns in lung cancer BALF exosome DNA. This panel achieved an area under the curve (AUC) of 0.97, with sensitivity and specificity rates of 88.24% and 97.14%, respectively. Each biomarker showed significantly higher mean methylation levels (MMLs) in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) compared to non-cancer groups, with fold changes from 1.7 to 13.36. The MMLs of the biomarkers were found to be moderately elevated with increasing patient age and smoking history, regardless of sex. A strong correlation was found between the MMLs and NSCLC stage progression, with detection sensitivities of 79% for early stages and 92% for advanced stages. In the validation cohort, the model demonstrated an AUC of 0.95, with 94% sensitivity and specificity. Sensitivity for early-stage NSCLC detection improved from 88.00% to 92.00% when smoking history was included as an additional risk factor.
Reference58 articles.
1. Lung Cancer 2020: Epidemiology, Etiology, and Prevention;Bade;Clin. Chest Med.,2020
2. The global burden of lung cancer: Current status and future trends;Leiter;Nat. Rev. Clin. Oncol.,2023
3. Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review;Tomasik;Transl. Lung Cancer Res.,2023
4. Babar, L., Modi, P., and Anjum, F. (2024). Lung Cancer Screening, StatPearls.
5. Circulating microbiome DNA as biomarkers for early diagnosis and recurrence of lung cancer;Chen;Cell Rep. Med.,2024